National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedEaton EF, Kulczycki A, Saag M
Immunization costs and programmatic barriers at an urban HIV clinic.
This study estimated costs of providing Gardasil, Prevnar, and Zostavax to eligible patients at a US Ryan White Part C academically affiliated HIV clinic in 2013. Its cost analysis of 3 vaccines showed great variation in insurance coverage, with potential losses of almost $100 000 for one HIV clinic if eligible patients received vaccinations in one calendar year.
AHRQ-funded; HS013852.
Citation: Eaton EF, Kulczycki A, Saag M .
Immunization costs and programmatic barriers at an urban HIV clinic.
Clin Infect Dis 2015 Dec;61(11):1726-31. doi: 10.1093/cid/civ637.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Healthcare Costs, Medication, Vaccination
Hellinger FJ
AHRQ Author: Hellinger FJ
Measuring the cost effectiveness of HIV prevention interventions in the US: pitfalls and problems.
The author comments on a review of cost-effectiveness studies of four types of HIV prevention interventions in the US. He agrees with the primary conclusion of the review that more cost-effectiveness research is needed to fill the knowledge gaps of interventions related to prevention for HIV-positives, condom distribution, and policy initiatives, in order to help guide the most efficient use of resources.
AHRQ-authored.
Citation: Hellinger FJ .
Measuring the cost effectiveness of HIV prevention interventions in the US: pitfalls and problems.
Appl Health Econ Health Policy 2015 Apr;13(2):129-33. doi: 10.1007/s40258-015-0158-5..
Keywords: Human Immunodeficiency Virus (HIV), Prevention, Healthcare Costs
Schackman BR, Fleishman JA, Su AE
AHRQ Author: Fleishman JA
The lifetime medical cost savings from preventing HIV in the United States.
The researchers sought to estimate the medical cost saved by averting 1 HIV infection in the United States. They found that the estimated discounted lifetime cost for persons who become HIV infected at age 35 is $326,500 (60% for antiretroviral medications, 15% for other medications, 25% nondrug costs.
AHRQ-authored; AHRQ-funded; 290201100007C.
Citation: Schackman BR, Fleishman JA, Su AE .
The lifetime medical cost savings from preventing HIV in the United States.
Med Care 2015 Apr;53(4):293-301. doi: 10.1097/mlr.0000000000000308..
Keywords: Medical Expenditure Panel Survey (MEPS), Healthcare Costs, Human Immunodeficiency Virus (HIV), Prevention